IRIS

1,1,1,2-Tetrachloroethane

CASRN 630-20-6 | DTXSID2021317

Noncancer Assessment

Reference Dose for Oral Exposure (RfD) (PDF) (13 pp, 117 K) Last Updated: 09/30/1987

System RfD (mg/kg-day) Basis PoD Composite UF Confidence
Hepatic, Urinary 3 x 10 -2 Mineralization of the kidneys in males, hepatic clear cell change in females LOAEL : 8.93 x 101
mg/kg-day
3000 Low

 


Reference Concentration for Inhalation Exposure (RfC) (PDF) (13 pp, 117 K)
Not assessed under the IRIS Program.

 

Cancer Assessment

Weight of Evidence for Cancer (PDF) (13 pp, 117 K) Last Updated: 03/01/1989

WOE Characterization Framework for WOE Characterization
C (Possible human carcinogen) Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986)
Basis:
  • Increased incidence of combined hepatocellular adenomas and carcinomas in female mice; inadequate evidence from human studies.
  • This may be a synopsis of the full weight-of-evidence narrative.

Quantitative Estimate of Carcinogenic Risk from Oral Exposure (PDF) (13 pp, 117 K)

Oral Slope Factor: 2.6 x 10-2 per mg/kg-day
Drinking Water Unit Risk: 7.4 x 10-7 per µg/L
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular adenoma or carcinoma (NTP, 1983)


Quantitative Estimate of Carcinogenic Risk from Inhalation Exposure (PDF) (13 pp, 117 K)

Inhalation Unit Risk: 7.4 x 10-6 per µg/m3
Extrapolation Method: Linearized multistage procedure, extra risk
Tumor site(s): Hepatic
Tumor type(s): Hepatocellular adenoma or carcinoma (NTP, 1983)


Additional EPA toxicity information may be available by visiting the following sites:

You will need Adobe Reader to view some of the files on this page. See EPA's PDF page to learn more.

Contact Us to ask a question, provide feedback or report a problem.